Megan N Januska

Dr. Megan N Januska

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2019 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
MJMegan N Januska
Megan N Januska
DGDavid L. Goldman
David L. Goldman
WWWilmore C Webley
Wilmore C Webley
WTW. Gerald Teague
W. Gerald Teague
RCRobyn T. Cohen
Robyn T. Cohen
AVAlfin Vicencio
Alfin Vicencio

1 February 2023 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
MJMegan N Januska
Megan N Januska
MWMartin J. Walsh
Martin J. Walsh
Cystic fibrosis (CF) is a multisystemic, autosomal recessive disorder caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, with the majority of morbidity and mortality extending from lung disease. Single-cell RNA sequencing (scRNA-seq) has been leveraged in the lung and elsewhere in the body to articulate discrete cell populations, describing cell types, states, and lineages as well as their roles in health and disease. In this translational review, we provide an overview of the current applications of scRNA-seq to the study of the normal and CF lungs, allowing the beginning of a new cellular and molecular narrative of CF lung disease, and we highlight some of the future opportunities to further leverage scRNA-seq and complementary single-cell technologies in the study of CF as we bridge from scientific understanding to clinical application.

19 December 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
APAum R. Patel
Aum R. Patel
AGAmit Garg
Amit Garg
HRHaylen T. Rosberger
Haylen T. Rosberger
SKShreyas Kowdle
Shreyas Kowdle
RRRebecca A. Reis
Rebecca A. Reis
JLJean K. Lim
Jean K. Lim
Formerly a common childhood pathogen, mumps virus (MuV) remains active worldwide, despite relatively high vaccine coverage. MuV is thought to infect the upper respiratory tract before disseminating to other organs; however, the early cellular targets of MuV in vivo are unknown. To address this, we generated a green fluorescent protein (GFP)-tagged vaccine strain (JL5) of MuV to infect leukocytic cell lines and found that replication was greatest in monocytes. Infection of peripheral blood mononuclear cells (PBMCs) also showed that both JL5 and a circulating strain of MuV (Iowa 2006; genotype G), preferentially infected monocytes. Further, monocyte-derived macrophages showed high susceptibility to MuV, with genotype G infecting macrophages to a much greater extent. While mice are generally resistant to MuV infection, we inoculated immunocompetent Rosa26-tdTomato mice intranasally with a GFP and Cre recombinase tagged MuV to determine whether monocytes/macrophages are important targets in vivo. We observed a small population of tdTomato + cells within the lungs, which included epithelial cells; however, the vast majority were alveolar macrophages (AMs). To validate these findings, we infected murine AMs isolated from Rosa26-tdTomato mice with the GFP and Cre recombinase tagged MuV and found that while MuV could enter AMs, as determined by tdTomato positivity, only a small percentage of these expressed GFP, suggesting that inhibition in murine cells occurs postentry. To translate these findings, we infected cells from human bronchoalveolar lavage fluid with MuV and found that most infected cells were AMs. These findings highlight the high susceptibility of AMs and provide a basis for early MuV pathogenesis and subsequent dissemination.

15 June 2022 in Pediatric Pulmonology
Verified
Journal Article
Closed access
MJMegan N Januska
Megan N Januska
ELElinor Langfelder-Schwind
Elinor Langfelder-Schwind
MBMaria N. Berdella
Maria N. Berdella

10 April 2026 in Nature Communications
Verified
Journal Article
Open access
MRMartha Rea-Moreno
Martha Rea-Moreno
LTLu Tian
Lu Tian
TTTara N. Tavakol
Tara N. Tavakol
MYMin-Chi Yang
Min-Chi Yang
NPNicole M. Pek
Nicole M. Pek
YCYa-Wen Chen
Ya-Wen Chen
The COVID-19 pandemic, caused by SARS-CoV-2, has underscored the urgency of understanding viral entry mechanisms to develop effective therapeutic strategies. SARS-CoV-2 primarily exploits angiotensin-converting enzyme 2 (ACE2) as its entry receptor and relies on the serine protease TMPRSS2 to prime its spike protein, enabling membrane fusion and infection. Traditionally, TMPRSS2 has been described as a cell surface protein, but our study reveals that in human lung epithelial cells, TMPRSS2 is largely absent from the plasma membrane and instead resides intracellularly. We show that TMPRSS2 is secreted together with ACE2 in extracellular vesicles (EVs) from lung epithelial cells, which are subsequently taken up by non-epithelial cells, specifically alveolar macrophages, endothelial cells, and pericytes, that do not express TMPRSS2 or ACE2 mRNAs under homeostatic conditions. This EV uptake deposits ACE2 and TMPRSS2 protein onto recipient cells, equipping them for SARS-CoV-2 entry. By transferring these viral entry proteins, EVs expand the spectrum of susceptible cell types in the lung, offering a new explanation for how the virus can infect diverse cell populations and cause widespread tissue damage. Identifying EVs as vehicles for delivering functional ACE2 and TMPRSS2 across cell types reveals a previously unrecognized pathway of viral entry with important implications for not only COVID-19 pathogenesis but also for other viral infections that exploit similar entry mechanisms. These findings open new avenues for therapeutic intervention aimed at disrupting EV-mediated protein transfer, potentially limiting viral dissemination and severity, and may also represent a generalizable mechanism exploited by other viral pathogens, highlighting the potential relevance of EV-mediated protein transfer beyond SARS-CoV-2.

17 November 2023 in Pediatric Pulmonology
Verified
Journal Article
Closed access
MJMegan N Januska
Megan N Januska
ELElinor Langfelder‐Schwind
Elinor Langfelder‐Schwind
AVAlfin Vicencio
Alfin Vicencio
MBMaria N. Berdella
Maria N. Berdella